Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
Read More
1 minute read

Arcutis Presents New Long-Term Data Of Roflumilast Cream 0.15% For The Treatment Of Mild To Moderate Atopic Dermatitis In Adults And Children Down To Age 6 At The Revolutionizing Alopecia Areata, Vitiligo, And Eczema Conference

By Benzinga Newsdesk
June 10, 2:32 PM
Investigational roflumilast cream 0.15% showed continued improvements in the signs and symptoms of AD, including itch, through 56 weeks of treatment 66.2% of participants treated with once-daily roflumilast cream

ARQT

Read More
1 minute read

Actinium Highlights Mutation Data From The Phase 3 SIERRA Trial Of Iomab-B And Novel Linker Technology To Support Solid Tumor Antibody Radiation Conjugate Development At The 2024 SNMMI Annual Meeting

By Benzinga Newsdesk
June 10, 8:37 AM
Iomab-B led bone marrow transplant improved survival in patients with high-risk relapsed or refractory acute myeloid leukemia including those with a TP53 mutationIomab-B safely delivered radiation to the target bone

ATNM

Read More
1 minute read

NRx Pharmaceuticals Publishes Shareholder Update Letter; Update Highlights Potential Implications Of The Company’s Recent Activities At The Annual Meeting Of The American Society Of Clinical Psychopharmacology

By Benzinga Newsdesk
June 10, 8:34 AM
The June 2024 meeting of the American Society for Clinical Psychopharmacology (ASCP) focused heavily on increasing use of intravenous ketamine and intranasal S-ketamine as the emerging standard of care for treating

NRXP

Read More
1 minute read

Eisai And Biogen Announced FDA Accepts Filing of LEQEMBI Supplemental Biologics License Application For IV Maintenance Dosing To Treat Early Alzheimer’s Disease

By Benzinga Newsdesk
June 9, 8:09 PM
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (NASDAQ:BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen")) announced today that the U.S.Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc.

BIIB